Boundless Bio Inc. (BOLD)

NASDAQ:BOLD

BOLD

Boundless Bio Inc.

RESEARCH TOOLSreports

Want to see BOLD full AI Analyst Report?

Boundless Bio Inc. (BOLD) Price & Analysis

45 Followers

BOLD Stock Chart & Stats

$1.27

-$0.03(-1.15%)

At close: Jan 08 4:00 PM EST

$1.27

-$0.03(-1.15%)

Day’s Range― - ―

52-Week Range$0.96 - $1.68

Previous CloseN/A

Volume5.57K

Average Volume (3M)178.65K

Market Cap

$31.00M

Enterprise Value$63.38M

Total Cash (Recent Filing)$92.85M

Total Debt (Recent Filing)$48.29M

Price to Earnings (P/E)―

Beta1.82

Next Earnings

Aug 17, 2026

EPS Estimate

-0.6

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.50

Shares Outstanding22,464,111

10 Day Avg. Volume162,533

30 Day Avg. Volume178,649

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.27

Price to Sales (P/S)0.00

P/FCF Ratio-0.57

Enterprise Value/Market Cap2.04

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-52.03

Enterprise Value/Ebitda-1.12

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.38

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe BBI-355 (CHK1) / BBI-825 (RNR) combo arm in the POTENTIATE trial is open for enrollment, suggesting potential data in 2026.

Efficacy And SafetyCHK1i + RNRi could achieve meaningful efficacy at tolerable exposures, avoiding the tox ceiling that crippled prior CHK1s.

Financial OutlookThe company reported $127mn in cash reiterating runway into 1H28, and expects PoC clinical readouts for both programs within this timeline.

Bears Say

Past Trial LimitationsPrior trials combined a CHK1 inhibitor and subtherapeutic gemcitabine and demonstrated responses in multiple tumor types, but were limited by hematological toxicities.

Price Target ReductionThe company reported a reduction in price target from $5 to $4 per share.

Boundless Bio Inc. News

Boundless Bio Halts Early Cancer Trial, Resetting Expectations for BOLD

Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Boundless Bio, Inc. (BOLD) has halted...

3d ago

BOLD

Boundless Bio reports Q1 EPS (60c), consensus (56c)

“We are encouraged by the progress of the KOMODO-1 trial,” said Zachary Hornby, President and Chief Executive Officer...

1M ago

BOLD

Boundless Bio presents preclinical data for BBI-940 therapy at AACR

Boundless Bio (BOLD) presents preclinical data supporting its lead ecDNA-directed therapy, BBI-940, at the American Association for Cancer...

2M ago

BOLD

Boundless Bio Terminates Major Long-Term San Diego Lease

The latest announcement is out from Boundless Bio Inc. ( ($BOLD) ). On April 13, 2026, Boundless Bio,...

2M ago

BOLD

Boundless Bio reports Q4 EPS (58c), consensus (52c)

“With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin...

3M ago

BOLD

Boundless Bio sees cash runway into 2H28

Cash, cash equivalents, and short-term investments totaled $107.6 million as of December 31, 2025. The Company expects its...

3M ago

BOLD

Boundless Bio Advances New Breast Cancer Drug BBI-940 Into First-in-Human Trial

Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Boundless Bio Inc. (BOLD) has launched...

4M ago

BOLD

Boundless Bio announces FDA accepted IND application of BBI-940

Boundless Bio (BOLD) announced that the U.S. Food and Drug Administration, FDA, has accepted its Investigational New Drug,...

5M ago

BOLD

Boundless ceases enrollment of Phase 1/2 Potentiate trial of BBI-355, BBI-825

Following a strategic portfolio review, Boundless Bio (BOLD) has elected to cease enrollment of the Phase 1/2 Potentiate...

5M ago

BOLD

Boundless Bio Terminates Early-Stage BBI-825 Cancer Trial: What Investors Should Know

Boundless Bio Inc. ($BOLD) announced an update on their ongoing clinical study. Study Overview The study, formally titled...

5M ago

BOLD

Boundless Bio Inc. Reports Q3 2025 Financial Results

Boundless Bio Inc. ( ($BOLD) ) has released its Q3 earnings. Here is a breakdown of the information...

7M ago

BOLD

Boundless Bio reports Q3 EPS (62c), consensus (58c)

We are advancing a pipeline rooted in tumor-enabling ecDNA biology to bring forward innovative therapies for patients with...

7M ago

BOLD

Boundless Bio sees cash runway into 1H28

Cash, cash equivalents, and short-term investments totaled $117.6 million as of September 30, 2025. Published first on TheFly...

7M ago

BOLD

Boundless Bio’s Innovative Cancer Study: A Potential Game-Changer?

Boundless Bio Inc. (($BOLD)) announced an update on their ongoing clinical study. Boundless Bio Inc. (BOLD) is conducting...

8M ago

BOLD

BOLD FAQ

What was Boundless Bio Inc.’s price range in the past 12 months?

Boundless Bio Inc. lowest stock price was $0.96 and its highest was $1.68 in the past 12 months.

What is Boundless Bio Inc.’s market cap?

Boundless Bio Inc.’s market cap is $31.00M.

When is Boundless Bio Inc.’s upcoming earnings report date?

Boundless Bio Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 66 days.

How were Boundless Bio Inc.’s earnings last quarter?

Boundless Bio Inc. released its earnings results on May 08, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.577 by -$0.023.

Is Boundless Bio Inc. overvalued?

According to Wall Street analysts Boundless Bio Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Boundless Bio Inc. pay dividends?

Boundless Bio Inc. does not currently pay dividends.

What is Boundless Bio Inc.’s EPS estimate?

Boundless Bio Inc.’s EPS estimate is -0.6.

How many shares outstanding does Boundless Bio Inc. have?

Boundless Bio Inc. has 22,464,111 shares outstanding.

What happened to Boundless Bio Inc.’s price movement after its last earnings report?

Boundless Bio Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.577. Following the earnings report the stock price went down -5.882%.

Which hedge fund is a major shareholder of Boundless Bio Inc.?

Currently, no hedge funds are holding shares in BOLD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Boundless Bio Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-53.60%

Trailing 12-Months

Asset Growth

-26.29%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Boundless Bio Inc.

Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.